Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
149 hedge funds and large institutions have $1.47B invested in Acceleron Pharma in 2017 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 55 increasing their positions, 35 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
57% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 35
41% more capital invested
Capital invested by funds: $1.05B → $1.47B (+$425M)
16% more funds holding
Funds holding: 128 → 149 (+21)
78% less call options, than puts
Call options by funds: $2.48M | Put options by funds: $11.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$33.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$31.4M |
| 3 |
Citigroup
New York
|
+$28.8M |
| 4 |
DM
Deerfield Management
New York
|
+$21.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.2M |
| 4 |
Millennium Management
New York
|
-$6.39M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$4.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
151
Harbourvest Partners
Boston,
Massachusetts
| – | -$1.56M | -51,296 | Closed |
|
|
SFM
152
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.06M | -35,000 | Closed |
|
|
GT
153
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$349K | -13,186 | Closed |
|
154
Creative Planning
Overland Park,
Kansas
| – | -$79K | -2,597 | Closed |
|
|
DADC
155
D.A. Davidson & Co
Great Falls,
Montana
| – | -$56K | -1,861 | Closed |
|
|
OAM
156
Oppenheimer Asset Management
New York
| – | -$25K | -837 | Closed |
|
|
TDC
157
Thompson Davis & Co
Richmond,
Virginia
| – | -$15K | -499 | Closed |
|
|
FC
158
Ferris Capital
Marlborough,
Massachusetts
| – | -$1K | -29 | Closed |
|
|
SMG
159
Spectrum Management Group
Indianapolis,
Indiana
| – | +$104 | +3 | New |
|
XLRN Hedge Fund Activity: Q3 2017 in Review
149 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2017, worth a combined $1.47B — up 41% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new XLRN positions and 10 closed out — a net gain of 22 holders — while 55 added to existing stakes and 35 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $33.4M. The largest seller was Fidelity Investments, cutting an estimated $34.9M.
- 149 institutional investors held Acceleron Pharma (XLRN) as of Q3 2017, up from 128 in Q2 2017.
- Funds reported $1.47B of Acceleron Pharma stock for Q3 2017, up 41% quarter-over-quarter.
- 32 funds opened new Acceleron Pharma positions in Q3 2017 and 10 closed out, a net change of +22 holders.
- The largest Acceleron Pharma buyer in Q3 2017 was Farallon Capital Management, an estimated $33.4M added.
- The largest Acceleron Pharma seller in Q3 2017 was Fidelity Investments, an estimated $34.9M sold.
Based on aggregated 13F filings for Q3 2017.